Protalix BioTherapeutics (PLX) Cash from Operations (2010 - 2026)

Protalix BioTherapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 22025000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 535.45% year-over-year to 22025000.0; the TTM figure through Mar 2026 stood at 15090000.0 (up 2738.11% YoY), while the FY2025 annual figure was 11993000.0, down 238.26% from the prior year.
• Cash from Operations was 22025000.0 for Q1 2026 at Protalix BioTherapeutics, up from 2030000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 22025000.0 in Q1 2026 to a low of 9204000.0 in Q3 2022.
• Historically, Cash from Operations has averaged 447764.71 across 5 years, with a median of 2998000.0 in 2023.
• The sharpest annual moves came in 2022 and 2026: Cash from Operations plunged 389.57% in 2022, then soared 535.45% in 2026.
• A 5-year view of Cash from Operations shows it stood at 2611000.0 in 2022, then soared by 237.69% to 3595000.0 in 2023, then gained by 11.02% to 3991000.0 in 2024, then plunged by 49.14% to 2030000.0 in 2025, then surged by 984.98% to 22025000.0 in 2026.
• The last three Cash from Operations figures came in at 22025000.0 (Q1 2026), 2030000.0 (Q4 2025), and 3732000.0 (Q3 2025), per Business Quant data.